Recombinant Proteins
Product List
SIGLEC9 Human
Sialic Acid Binding Ig Like Lectin 9 Human Recombinant
SIGLEC9 Human Recombinant produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 573 amino acids (18-348a.a.) and having a molecular mass of 63.3kDa (Molecular size on SDS-PAGE will appear at approximately 70-100kDa).
SIGLEC9 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
SIGLEC10 Human
Sialic Acid Binding Ig Like Lectin 10 Human Recombinant
SIGLEC10 Human produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 678 amino acids (17-455 a.a.) and having a molecular mass of 75.6kDa. SIGLEC10 is expressed with a 239 hIgG-His-tag at C-Terminus and purified by proprietary chromatographic techniques.
SIGLEC5 Human
Sialic Acid Binding Ig Like Lectin 5 Human Recombinant
SIGLEC5 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 667 amino acids (17-441a.a.) and having a molecular mass of 74.2kDa (Molecular size on SDS-PAGE will appear at approximately 70-100kDa). SIGLEC5 is expressed with a 239 amino acid hIgG-His Tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
SIGLEC6 Human
Sialic Acid Binding Ig Like Lectin 6 Human Recombinant
SIGLEC6 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 563 amino acids (27-347a.a.) and having a molecular mass of 62.6kDa (Molecular size on SDS-PAGE will appear at approximately 70-100kDa). SIGLEC6 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
SIGLEC7 Human
Sialic Acid Binding Ig Like Lectin 7 Human Recombinant
SIGLEC7 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 577 amino acids (19-353a.a.) and having a molecular mass of 64.2kDa. SIGLEC7 is expressed with a 239 amino acid hIgG-His-tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
Introduction
SIGLECs (Sialic acid-binding immunoglobulin-like lectins) are a family of cell surface proteins that bind sialic acid. They are primarily found on the surface of immune cells and are a subset of the I-type lectins . There are 14 different mammalian SIGLECs, each providing an array of functions based on cell surface receptor-ligand interactions . SIGLECs are classified into two groups: the highly conserved group (including Sialoadhesins, CD22, MAG, and SIGLEC-15) and the CD33-related SIGLECs .
SIGLECs are predominantly expressed on immune cells such as macrophages, B cells, T cells, dendritic cells, and natural killer cells . They are type I transmembrane proteins with an N-terminal V-type immunoglobulin domain that acts as the binding receptor for sialic acid . The expression patterns and tissue distribution of SIGLECs vary, with some being specific to certain cell types and tissues .
The primary function of SIGLECs is to bind glycans containing sialic acids, which can be used in cell adhesion, cell signaling, and other processes . SIGLECs play crucial roles in immune responses by recognizing and binding to sialic acids on pathogens, thereby modulating immune cell activation, proliferation, and apoptosis . They are involved in pathogen recognition and help in distinguishing self from non-self .
SIGLECs mediate their effects through interactions with other molecules and cells. They recognize sialic acids on the surface of cells and pathogens, leading to various downstream signaling cascades . These interactions can result in either inhibitory or activating signals, depending on the specific SIGLEC and its binding partners . For example, some SIGLECs contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that down-regulate signaling pathways, while others interact with adapter proteins like DAP12 to activate immune responses .
The expression and activity of SIGLECs are tightly regulated through various mechanisms. Transcriptional regulation involves specific transcription factors that control SIGLEC gene expression . Post-translational modifications, such as phosphorylation, also play a critical role in modulating SIGLEC activity and signaling . Additionally, the interaction with sialic acid ligands can influence the stability and localization of SIGLECs on the cell surface .
SIGLECs have significant applications in biomedical research, diagnostic tools, and therapeutic strategies. They are being explored as potential biomarkers for various diseases, including cancer and infectious diseases . Therapeutically, targeting SIGLECs with synthetic ligands or monoclonal antibodies holds promise for modulating immune responses in conditions like cancer and autoimmune diseases . SIGLECs are also being investigated for their role in enhancing the efficacy of immunotherapies .
Throughout the life cycle, SIGLECs play essential roles from development to aging and disease. During development, SIGLECs are involved in the regulation of immune cell differentiation and maturation . In aging, changes in SIGLEC expression and function can impact immune system efficiency and contribute to age-related diseases . In disease contexts, SIGLECs are implicated in various pathological processes, including chronic inflammation, neurodegeneration, and cancer .
